STING1 and neoplasm: As an alternative to these macromolecule-based strategies, we seek to develop a small-molecule-based prodrug responsive to enzymes overexpressed in the tumour microenvironment (TME), thereby enabling a preferential activation of the STING agonist in the tumour.